Nuclear exclusion of YAP exacerbates podocyte apoptosis and disease progression in Adriamycin-induced focal segmental glomerulosclerosis
Open Access
- 17 November 2020
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 101 (2) , 258-270
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Growth Control by Committee: Intercellular Junctions, Cell Polarity, and the Cytoskeleton Regulate Hippo SignalingDevelopmental Cell, 2012
- Focal Segmental GlomerulosclerosisNew England Journal of Medicine, 2011
- E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway componentsProceedings of the National Academy of Sciences, 2011
- Yap1 Acts Downstream of α-Catenin to Control Epidermal ProliferationCell, 2011
- Angiomotin is a novel Hippo pathway component that inhibits YAP oncoproteinGenes & Development, 2011
- A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCPGenes & Development, 2010
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAPCell, 2005